Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Subscribe To Our Newsletter & Stay Updated
